Sign in
CompletedPhase 3

ALBumin Italian Outcome Septic Shock-BALANCED Trial (ALBIOSS-BALANCED)

Key facts

Who runs it
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Where
Italy37 sites in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 3
People taking part
1,319 people enrolled
Started
7 May 2019
Ended
31 Jan 2025
Type of study
Interventional, 4 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Albumin
  • Balanced
Record updated
5 March 2025

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patients with septic shock if they meet the two following criteria:
  • Presence of an infection (known or suspected) in at least one site:; Lung; Abdomen; Urinary tract; Others (blood, skin and soft tissues, central nervous system, bones and joints, cardiac system, reproductive organs)
  • Presence of a severe and acute, sepsis-related cardiovascular failure (as assessed by the SOFA score - see Annex 1), requiring vasopressor to maintain mean arterial pressure >=65 mmHg, despite adequate volume resuscitation a) Cardiovascular SOFA score > 2 (3 or 4) If the patient is unable to provide informed consent, she/he can be included in the trial provided that the requirements of ongoing laws are fulfilled; details on this approach are provided in the protocol, par 11.1 and related Annex 3. The patient will be informed about having been included in a clinical trial, as soon as she/he will regain consciousness

Who cannot take part

  • Severe congestive heart failure (NYHA III and IV classes)
  • Presence of chronic end-stage renal disease
  • Known or suspected adverse reaction to albumin administration
  • Clinical situations in which the use of albumin is known or supposed to be clinically beneficial (hepatic cirrhosis with ascites, malabsorption syndrome or protein-losing enteropathy, nephrotic syndrome, burns)
  • Severe hyperkalemia (> 6 mmol/L)
  • Laboratory confirmation for SARS-CoV-2 infection
  • Age < 18 years
  • Moribund state
  • Septic shock in patients with traumatic brain injury or a clinically active cerebral lesion (known or suspected)
  • More than 24 hours after the onset of septic shock
  • Religious objection to the administration of human blood products
  • Known or suspected pregnancy based on patient information
  • Enrollment in other experimental interventional studies

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Septic shock is a devastating condition often observed in ICU. It is characterized by pro-inflammatory and immune responses, organ failures, high incidence of AKI and lethality. Fluid resuscitation is pivotal as supportive therapy. At present, there are no effective therapies to improve survival of such clinical condition, often characterized by a mortality as high as 40% during the first 90 days from diagnosis.

Read full original descriptionShow less

This project proposes a large 2-by-2 factorial randomized clinical trial testing the efficacy of albumin and the low- chloride balanced crystalloid solutions (either Ringer Lactate, Ringer Acetate, or Crystalsol - BAL) in septic shock.

The investigators have recently concluded a multicenter, randomized trial, the ALBIOS trial, in which, in a post-hoc analysis, albumin, in addition to crystalloids, reduced 90-day mortality in patients with septic shock, as compared to crystalloids alone (Caironi P et al, 2014). Crystalloids with supra-physiological chloride content may deteriorate renal perfusion, increasing the risk of acute kidney injury (AKI) and mortality.

The 4 groups in the trial

  • Albumin + BalancedTreatment being tested

    Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination. Balanced crystalloid solutions According to the preference and the standard use of the participating center: * Ringer Lactate * Ringer Acetate * Crystalsol

    Treatment: Albumin and Balanced

  • Albumin + SalineTreatment being tested

    Human Albumin In parallel with fluid administration for volume resuscitation, patients will receive 400 ml of 20% albumin solution both at randomization (D0) and at day 1 (D1). Subsequently, from day 2 (D2) until day 90 (D90) or ICU discharge (whichever comes first), 20% albumin will be administered on a daily basis, to maintain serum albumin concentration equal to or greater than 30 g/L, based upon serum albumin determination. Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).

    Treatment: Albumin

  • BalancedTreatment being tested

    Balanced crystalloid solutions (Ringer Lactate, Ringer Acetate, Crystalsol)

  • SalineNo study treatment, for comparison

    Normal Saline Na+ 154 mEq/L, Cl- 154 mEq/L (0.9% NaCl).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy of Albumin Replacement and Balanced Solution in Patients With Septic Shock (the ALBIOSS-BALANCED Trial): a 2-by-2 Factorial, Investigator-initiated, Open- Label, Multicenter, Randomized, Controlled Trial
Record updated
5 March 2025